PE20050445A1 - Forma de presentacion del naproxeno sodico - Google Patents
Forma de presentacion del naproxeno sodicoInfo
- Publication number
- PE20050445A1 PE20050445A1 PE2004001035A PE2004001035A PE20050445A1 PE 20050445 A1 PE20050445 A1 PE 20050445A1 PE 2004001035 A PE2004001035 A PE 2004001035A PE 2004001035 A PE2004001035 A PE 2004001035A PE 20050445 A1 PE20050445 A1 PE 20050445A1
- Authority
- PE
- Peru
- Prior art keywords
- weight
- sodium
- tablet
- core
- naproxen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPRIMIDOS NO EFERVECENTES PARA LA ADMINISTRACION ORAL DEL NAPROXENO SODICO O EL ACIDO (S)-2-(6-METOXI-2-NAFTIL)PROPIONICO QUE COMPRENDEN UN NUCLEO DE COMPRIMIDO Y SI SE DESEA UN RECUBRIMIENTO DE AZUCAR O DE UNA PELICULA SOBRE EL NUCLEO DEL COMPRIMIDO DONDE EL NUCLEO CONSTA DE 30% A 99% EN PESO DE NAPROXENO Y DE 70 HASTA 1% EN PESO DE COMPONENTES DE SUSTANCIAS AUXILIARES QUE COMPRENDEN AL MENOS UN ELEMENTO AUXILIAR BASICO RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO. EL NUCLEO DEL COMPRIMIDO CONSTA DE 30% A 95% EN PESO DE NAPROXENO SODICO, ENTRE 60% A 75% EN PESO DE NAPROXENO SODICO, ENTRE OTROS. EL COMPRIMIDO PRESENTA UN CONTENIDO DE AGUA DE 0,05 A 14% EN PESO Y SUSTANCIAS AUXILIARES BASICAS EN UNA CANTIDAD TOTAL MINIMA DE UN 5% EN PESO, RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO. LA SUSTANCIA AUXILIAR BASICA SE ELIGE DE BICARBONATO SODICO, POTASICO CARBONATO SODICO, ENTRE OTROS. LA SUSTANCIA AUXILIAR SE SELECCIONA ADEMAS DE AZUCARES, HEXOSAS, ALMIDONES, CICLODEXTRINAS, POLIVINILPIRROLIDONAS, MALTODEXTRINA, ENTRE OTROS. EL COMPRIMIDO COMPRENDE ADEMAS UN DISGREGANTE SELECCIONADO DE CROSCARMELOSA, CROSPOVIDONA, ALMIDON DE CARBOXIMETILO SODICO RETICULADO; UN TENSIOACTIVO SELECCIONADO DE LAURILSULFATO SODICO, DODECILSULFATO SODICO, POLISORBATO, ENTRE OTROS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH18482003 | 2003-10-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20050445A1 true PE20050445A1 (es) | 2005-06-18 |
Family
ID=34529359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2004001035A PE20050445A1 (es) | 2003-10-30 | 2004-10-27 | Forma de presentacion del naproxeno sodico |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070134317A1 (es) |
EP (1) | EP1684728B1 (es) |
JP (1) | JP2007509862A (es) |
AR (1) | AR046213A1 (es) |
AT (1) | ATE442840T1 (es) |
BR (1) | BRPI0415624A (es) |
CA (1) | CA2543709A1 (es) |
CR (1) | CR8406A (es) |
DE (1) | DE602004023220D1 (es) |
EC (1) | ECSP066587A (es) |
ES (1) | ES2333332T3 (es) |
PA (1) | PA8616101A1 (es) |
PE (1) | PE20050445A1 (es) |
UY (1) | UY28583A1 (es) |
WO (1) | WO2005041938A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2624585T3 (es) * | 2004-05-28 | 2017-07-17 | Imaginot Pty Ltd. | Sistema de suministro de compuesto terapéutico oral |
US9205054B2 (en) | 2005-03-22 | 2015-12-08 | Losan Pharma Gmbh | Solubilized ibuprofen |
US9757455B2 (en) | 2005-11-28 | 2017-09-12 | Johnson & Johnson Consumer Inc. | Oral therapeutic compound delivery system |
GB201506755D0 (en) * | 2015-04-21 | 2015-06-03 | Reckitt Benckiser Llc | Novel pharmaceutical formulation |
WO2017062997A1 (en) * | 2015-10-09 | 2017-04-13 | Reckitt Benckiser Llc | Pharmaceutical formulation |
JP7163015B2 (ja) | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 経口固形組成物 |
JP7163014B2 (ja) * | 2016-10-31 | 2022-10-31 | エスエス製薬株式会社 | 感冒薬 |
US11779541B2 (en) | 2019-03-26 | 2023-10-10 | Johnson & Johnson Consumer Inc. | Immediate release dosage form |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2470599A1 (fr) * | 1979-12-07 | 1981-06-12 | Panoz Donald | Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus |
US5034416A (en) * | 1988-01-19 | 1991-07-23 | Smith Walton J | Carboxylic acid compositions |
PT96229B (pt) * | 1989-12-22 | 1998-06-30 | Syntex Pharma Int | Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico |
US5358717A (en) * | 1989-12-22 | 1994-10-25 | Syntex (U.S.A.) Inc. | Directly-compressible naproxen or naproxen sodium compositions |
IT1272149B (it) * | 1993-03-26 | 1997-06-11 | Zambon Spa | Composizione farmeceutiche ad attivita' analgesica |
GB9603699D0 (en) * | 1996-02-21 | 1996-04-17 | Boots Co Plc | Therapeutic composition |
US5948787A (en) * | 1997-02-28 | 1999-09-07 | Alza Corporation | Compositions containing opiate analgesics |
JPH10298072A (ja) * | 1997-04-17 | 1998-11-10 | Panacea Biotec Ltd | 非ステロイド性抗炎症剤の遷移金属錯体 |
NZ333474A (en) * | 1998-01-02 | 1999-06-29 | Mcneil Ppc Inc | A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat |
US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
US6383515B2 (en) * | 1999-05-28 | 2002-05-07 | Sawyer Maryjean | Solvent system for enhancing solubility |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030008003A1 (en) * | 2001-04-10 | 2003-01-09 | Fahkreddin Jamali | Compositions for enhanced absorption of NSAIDs |
WO2002083110A2 (en) * | 2001-04-10 | 2002-10-24 | Zagros Pharma, Inc. | Animal model for evaluating analgesics |
-
2004
- 2004-10-27 UY UY28583A patent/UY28583A1/es not_active Application Discontinuation
- 2004-10-27 PE PE2004001035A patent/PE20050445A1/es not_active Application Discontinuation
- 2004-10-28 AR ARP040103936A patent/AR046213A1/es not_active Application Discontinuation
- 2004-10-28 PA PA20048616101A patent/PA8616101A1/es unknown
- 2004-10-29 DE DE602004023220T patent/DE602004023220D1/de active Active
- 2004-10-29 AT AT04761983T patent/ATE442840T1/de not_active IP Right Cessation
- 2004-10-29 CA CA000000008A patent/CA2543709A1/en not_active Abandoned
- 2004-10-29 US US10/577,197 patent/US20070134317A1/en not_active Abandoned
- 2004-10-29 ES ES04761983T patent/ES2333332T3/es active Active
- 2004-10-29 WO PCT/CH2004/000655 patent/WO2005041938A1/en active Application Filing
- 2004-10-29 JP JP2006537031A patent/JP2007509862A/ja active Pending
- 2004-10-29 BR BRPI0415624-2A patent/BRPI0415624A/pt not_active IP Right Cessation
- 2004-10-29 EP EP04761983A patent/EP1684728B1/en active Active
-
2006
- 2006-05-15 CR CR8406A patent/CR8406A/es not_active Application Discontinuation
- 2006-05-29 EC EC2006006587A patent/ECSP066587A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1684728A1 (en) | 2006-08-02 |
AR046213A1 (es) | 2005-11-30 |
US20070134317A1 (en) | 2007-06-14 |
CA2543709A1 (en) | 2005-05-12 |
ECSP066587A (es) | 2006-10-17 |
JP2007509862A (ja) | 2007-04-19 |
PA8616101A1 (es) | 2005-08-04 |
WO2005041938A1 (en) | 2005-05-12 |
ES2333332T3 (es) | 2010-02-19 |
DE602004023220D1 (de) | 2009-10-29 |
UY28583A1 (es) | 2005-05-31 |
BRPI0415624A (pt) | 2006-12-12 |
ATE442840T1 (de) | 2009-10-15 |
EP1684728B1 (en) | 2009-09-16 |
CR8406A (es) | 2008-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110010A2 (es) | Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo | |
ES2606342T3 (es) | Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos | |
WO2007131088A3 (en) | Oral rehydration compositions | |
PE20080400A1 (es) | Composicion farmaceutica para la anticoncepcion y para reducir el riesgo de malformaciones congenitas | |
WO2005092271A8 (en) | Film compositions | |
PA8625001A1 (es) | Composiciones de pelicula | |
PE20050445A1 (es) | Forma de presentacion del naproxeno sodico | |
ATE493973T1 (de) | Irbesartan enthaltende pharmazeutische zusammensetzung | |
AR062980A1 (es) | Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida | |
AR048864A1 (es) | Tabletas dispersables que comprenden un derivado de acido benzoico | |
BRPI0417043A (pt) | composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição | |
DE60332393D1 (de) | Flüssige pharmazeutische zusammensetzung mit pyridonderivaten | |
CO5670371A2 (es) | Composiciones limpiadoras en la forma de una tableta | |
CO6220900A2 (es) | Forma dosificadora novedosa | |
NO20083027L (no) | Kontrollert frigivelses-fastformpreparat | |
MXPA05007909A (es) | Composiciones limpiadoras en la forma de una tableta. | |
HN2003000185A (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiemto para su preparacion, medicamentos que comprenden estso compuestos y su uso. | |
AR026968A1 (es) | Una tableta matriz que permite la liberacion prolongada de trimetazidina lluego de su administracion por via oral | |
CR8003A (es) | Composiciones limpiadoras en la forma de una tableta | |
ES2143481T3 (es) | Comprimido de valproato de sodio de liberacion lenta. | |
CL2007003451A1 (es) | Composicion farmaceutica solida oral que comprende un principio activo y polivinilpirrolidona (pvp) entre 1,0-25%, cpaa entre 0,5-10%, el principio activo consiste en una sal hidrosoluble de metal alcalino, de metal alcalino-terreo, una sal de mezcla | |
EA201000701A1 (ru) | 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465 | |
CY1110478T1 (el) | Φαρμακευτικη συνθεση που προοριζεται για χορηγηση απο το στομα ενος παραγωγου πυραζολο-3-καρβοξαμιδιου | |
MA55071A (fr) | Régime d'administration de solutions d'hormone thyroïdienne t4 à absorption orale élevée | |
ATE489943T1 (de) | Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |